research Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
Search
for
Sort by
Research
360-390 / 1000+ results 
research Trichodysplasia of immunosuppression treated with oral valganciclovir
Oral valganciclovir improved a patient's skin condition caused by immunosuppression.
research Dr Reddy's Laboratories has announced the launch of its finasteride and simvastatin tablets,
research Inhibition of 17α-hydroxylase/C17,20 lyase reduces gating deficits consequent to dopaminergic activation
Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib
Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research Effect of interferon therapy on quality of life in patients with chronic hepatitis B
Interferon therapy improves quality of life for chronic hepatitis B patients.
research Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
research Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research Megaloblastic Anemia in a Patient on Peritoneal Dialysis Returning from Kenya
Proguanil can cause anemia and hair loss in kidney disease patients.
research An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa
Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
research Editor’s picks January 2021
PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.
research Synthesis and Study of Some 17a-aza-D-homo Steroids as 5α-Reductase Inhibitors
The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.
research Development and evaluation of antisense shRNA-encoding plasmid loaded solid lipid nanoparticles against 5-α reductase activity
The new particle system could be a promising treatment for diseases related to the 5-α reductase enzyme.
research Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
research Proxalutamide (GT0918) Reduces the Rate of Hospitalization in mild-to-moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Two-Arm Parallel Trial
Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
research THE USE OF TOFACITINIB IN THE TREATMENT OF IMMUNE-MEDIATED UNIVERSAL ALOPECIA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT
Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
research Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19
A standardized drug development platform is essential for efficient and effective drug repurposing, especially during pandemics.
research Finasteride plus doxazosin combination tops in BPH
research A population pharmacokinetic model for individualized regimens of finasteride according to CYP3A5 genotype and liver function
Finasteride dosages should be adjusted based on CYP3A5 genotype and liver function to avoid side effects.
research Ginecomastia por finasteride
research Identification of neprilysin as a potential target of arteannuin using computational drug repositioning
Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.
research Alopecia Universalis: an extremely rare but probable adverse effect of adalimumab
Adalimumab can cause complete hair loss in rare cases.
research A New Look at the 5á-Reductase Inhibitor Finasteride
Finasteride, a medication, is being re-evaluated for its effects and uses.
research Azathioprine
Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.
research Cepharanthine: A review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19
Cepharanthine could be a strong antiviral against COVID-19.
research BH31 Ritlecitinib for severe alopecia areata: does regional prescribing match national guidance?
Regional prescribing of ritlecitinib mostly follows national guidance, but psychological assessments and consistent scoring need improvement.